Integrated Biopharma, Inc.
INBP
$0.30
$0.00-0.27%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -122.20% | 56.28% | 621.43% | 1,181.03% | 341.04% |
| Total Depreciation and Amortization | 2.38% | 2.65% | 3.93% | 4.66% | 5.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 75.87% | 158.48% | 320.90% | 134.85% | 142.28% |
| Change in Net Operating Assets | 266.29% | 68.81% | -101.88% | -35.69% | 59.65% |
| Cash from Operations | 34.99% | 843.90% | 118.98% | 2,359.65% | 1,106.52% |
| Capital Expenditure | 47.40% | 46.06% | 65.46% | 18.35% | -500.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 44.97% | 43.61% | 62.93% | 18.16% | -506.32% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 17.86% | 69.23% | 80.95% | 56.10% | 31.71% |
| Issuance of Common Stock | 277.78% | -- | 561.54% | 38.46% | 38.46% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 550.00% | 289.74% | 368.97% | 100.00% | 64.29% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 65.01% | 861.92% | 436.84% | 284.87% | 589.80% |